Evidence map›Paper›PMID 37662226›Full record

ArticlemedRxiv : the preprint server for health sciences2023

SARS-CoV-2 shedding and evolution in immunocompromised hosts during the Omicron period: a multicenter prospective analysis.

Zoe Raglow, Diya Surie, James D Chappell, Yuwei Zhu, Emily T Martin, Jennie H Kwon, Anne E Frosch, Amira Mohamed, Julie Gilbert, Emily E Bendall and 16 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 1 country.

Zoe RaglowDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Diya SurieNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.
James D ChappellDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
Yuwei ZhuDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Emily T MartinSchool of Public Health, University of Michigan, Ann Arbor, Michigan.
Jennie H KwonDepartment of Medicine, Washington University, St. Louis, Missouri.
Anne E FroschDepartment of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota.
Amira MohamedDepartment of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Julie GilbertDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Emily E BendallDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Auden BahrComputational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan.
Natasha HalasaDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
H Keipp TalbotDepartments of Medicine and Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.
Carlos G GrijalvaDepartment of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.
Adrienne BaughmanDepartment of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Kelsey N WomackVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee.
Cassandra JohnsonDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Sydney A SwanDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Emilia KoumansDivision of STD Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.
Meredith L McMorrowNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.
Jennifer L HarcourtNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.
Lydia J AthertonNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.
Ashley BurroughsNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.
Natalie J ThornburgNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.
Wesley H SelfVanderbilt Institute for Clinical and Translational Research and Department of Emergency Medicine and, Vanderbilt University Medical Center, Nashville, Tennessee.
Adam S LauringDepartments of Internal Medicine and Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan.
Vanderbilt University Medical Center · USCenters for Disease Control and Prevention · USUniversity of Michigan · USAlbert Einstein College of Medicine · USHennepin County Medical Center · USWashington University in St. Louis · US

Funding

PULMONARY CELLULAR AND MOLECULAR BIOLOGY TRAININGT32HL007749 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Pickett Dickson · 1993 to 2026
$19.9M
Memory T follicular helper cell kinetics and localization during recall immune responses to tetanus vaccinationK08AI141761 · NIAID · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI FROSCH, ANNE ELIZABETH PARKER · 2019 to 2023
$984k
Mentoring in transmission of influenza and strategies for preventionK24AI148459 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GRIJALVA, CARLOS G · 2020 to 2024
$893k
NHLBI NIH HHS T32 HL007749NIAID NIH HHS K08 AI141761NIAID NIH HHS K24 AI148459
6 · The paper itself

Abstract

Background: Prolonged SARS-CoV-2 infections in immunocompromised hosts may predict or source the emergence of highly mutated variants. The types of immunosuppression placing patients at highest risk for prolonged infection and associated intrahost viral evolution remain unclear. Methods: Adults aged ≥18 years were enrolled at 5 hospitals and followed from 4/11/2022 - 2/1/2023. Eligible patients were SARS-CoV-2-positive in the previous 14 days and had a moderate or severely immunocompromising condition or treatment. Nasal specimens were tested by rRT-PCR every 2-4 weeks until negative in consecutive specimens. Positive specimens underwent viral culture and whole genome sequencing. A Cox proportional hazards model was used to assess factors associated with duration of infection. Results: We enrolled 150 patients with: B cell malignancy or anti-B cell therapy (n=18), solid organ or hematopoietic stem cell transplant (SOT/HSCT) (n=59), AIDS (n=5), non-B cell malignancy (n=23), and autoimmune/autoinflammatory conditions (n=45). Thirty-eight (25%) were rRT-PCR-positive and 12 (8%) were culture-positive ≥21 days after initial SARS-CoV-2 detection or illness onset. Patients with B cell dysfunction had longer duration of rRT-PCR-positivity compared to those with autoimmune/autoinflammatory conditions (aHR 0.32, 95% CI 0.15-0.64). Consensus (>50% frequency) spike mutations were identified in 5 individuals who were rRT-PCR-positive >56 days; 61% were in the receptor-binding domain (RBD). Mutations shared by multiple individuals were rare (<5%) in global circulation. Conclusions: In this cohort, prolonged replication-competent Omicron SARS-CoV-2 infections were uncommon. Within-host evolutionary rates were similar across patients, but individuals with infections lasting >56 days accumulated spike mutations, which were distinct from those seen globally.

Indexed as

COVID-19evolutionimmunocompromiseprolonged replicationSARS-CoV-2

Identifiers

PMID37662226
PMCPMC10473782
OpenAlexW4386165824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.